When can apixaban (Eliquis) be safely restarted after stopping a therapeutic unfractionated heparin infusion in a patient with normal renal function?

Timing of Apixaban Restart After Stopping Unfractionated Heparin

Apixaban can be started immediately at the time of the next scheduled dose after discontinuing unfractionated heparin, without any waiting period or bridging, in patients with normal renal function.

Pharmacokinetic Rationale

Unfractionated heparin has a short half-life of approximately 60-90 minutes, meaning anticoagulant activity dissipates rapidly after stopping the infusion 1. After 4-6 hours (approximately 4-5 half-lives), UFH is effectively cleared from circulation 1. This rapid clearance eliminates concerns about overlapping anticoagulant effects when transitioning to apixaban.

Direct Transition Protocol

The FDA-approved apixaban label explicitly states: "Discontinue the anticoagulant other than warfarin and begin taking apixaban at the usual time of the next dose of the anticoagulant other than warfarin" 2. This means:

• Stop the heparin infusion
• Start apixaban at the time the next heparin dose would have been due
• No waiting period is required
• No bridging anticoagulation is necessary 2

This approach is fundamentally different from warfarin transitions, which require overlap due to warfarin's delayed onset of action 3.

Post-Procedural Context

If the heparin was being used in the perioperative setting, the timing differs based on bleeding risk 4, 3:

• Standard procedures with adequate hemostasis: Resume apixaban 6-8 hours after the procedure 3
• High bleeding risk procedures: Consider delaying full-dose anticoagulation for 24-72 hours, potentially using prophylactic-dose LMWH as a bridge if thrombotic risk is high 4, 3
• The first therapeutic dose of apixaban should be given 12 hours after the last prophylactic LMWH dose if bridging was used 4

Critical Pitfall to Avoid

Do not confuse the transition from heparin to apixaban with the transition from apixaban to heparin. When switching from apixaban to warfarin, you need parenteral anticoagulation overlap 2. However, when switching from heparin to apixaban, no overlap or waiting period is needed because apixaban has rapid onset of action (peak levels in 3-4 hours) 3.

Special Consideration: Recent DOAC Use

If the patient was taking apixaban or another DOAC before being bridged to heparin, residual DOAC activity may persist for 24-72 hours and can interfere with anti-Xa monitoring of heparin 5, 6. In one case report, detectable apixaban levels persisted for >10 days in an elderly patient with chronic kidney disease 6. However, this does not affect the timing of restarting apixaban after heparin—you still restart immediately at the next scheduled dose 2.

Renal Function Considerations

In patients with severe renal dysfunction, UFH clearance may be slightly prolonged (consider 8-12 hours for complete clearance), though UFH is primarily hepatically cleared 1. Apixaban itself requires dose reduction only in specific circumstances (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL—requiring 2 of 3 criteria for dose reduction to 2.5 mg twice daily) 2. The transition timing from heparin remains unchanged regardless of renal function.

Dosing After Transition

Use the appropriate apixaban dose based on indication 2:

• Acute VTE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily
• Atrial fibrillation: 5 mg twice daily (or 2.5 mg twice daily if dose reduction criteria met)
• VTE secondary prevention: 2.5 mg twice daily after completing at least 6 months of treatment